Skip to main content
. Author manuscript; available in PMC: 2021 Feb 15.
Published in final edited form as: Cancer. 2019 Nov 12;126(4):894–907. doi: 10.1002/cncr.32600

Figure 4. Chloroquine sensitizes Patient-derived and cell line-derived human ovarian cancer xenografts to olaparib.

Figure 4.

A. PH063-PDX model was treated with 50 mg/kg chloroquine (CQ), 50 mg/kg olaparib or a combination of olaparib plus CQ, by daily gavage for 8 weeks (n=12). B and D. LC3 protein was detected by immunohistochemistry using paraffin-embedded sections of tumor excised from PDX mice treated with olaparib or diluent. C. OVCAR8 cells (5× 106) were injected intraperitoneally into nu/nu mice that were treated with 40 mg/kg olaparib, 50mg/kg CQ or both for 4 weeks. After treatment, mice were sacrificed, and tumor weight were measured. The tumor weight in each group is plotted (n=7 in each group).